Galderma gets EC OK on Mirvaso; Neurocrine out to raise about $126M;

@FierceBiotech: Novartis takes the transparency 'pledge,' but is it too little, too late? More | Follow @FierceBiotech

@JohnCFierce: Are Lilly and J&J on the short list? Mystery U.S. pharma company circles Andromeda and its PhIII diabetes drug. Story | Follow @JohnCFierce

@DamianFierce: With a reported $330M+ on the way, Abingworth is the latest biotech VC amassing a new fund. News | Follow @DamianFierce

@EmilyMFierce: Trending at FierceBiotechResearch.com --> Scientist: Let's not discredit acid-bath stem cell studies--yet. More | Follow @EmilyMFierce

> The EC has approved Galderma's Mirvaso for facial redness associated with rosacea. The company, which has been undergoing a restructuring, won FDA approval for the therapy last year. Release

> Neurocrine Biosciences ($NBIX) is planning to raise about $126 million in a follow-on offering. A few weeks ago the company saw its shares rocket up on the successful conclusion of a Phase IIb study Release

> The news that Dara BioSciences won orphan drug status at the FDA sent its stock up yesterday. Story

Medical Device News

@FierceMedDev: Foundation Medicine ended its first (partial) year as a public company revenue still heading higher. Release | Follow @FierceMedDev

@MarkHFierce: In the (marathon) battle to overturn the device tax, word from a pediatric device company CEO might help. More | Follow @MarkHFierce

@MichaelGFierce: FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. News | Follow @MichaelGFierce

@EmilyWFierce: Seno Medical Instruments raises $39M in a critical funding round for breast cancer dx device. More | Follow @EmilyWFierce

@GalenMoore: FDA may have gone too far, reading personal emails of medtech approval whistleblowers. Story | Follow @GalenMoore

> Qiagen has unveiled a low-tech HPV test in India. Piece

> A pediatric device company CEO speaks out against the device tax. More

Pharma News

@FiercePharma: GSK's new respiratory launches will give its revamped sales model a workout - FP. Story | Follow @FiercePharma

@TracyStaton: ICYMI: Thumbs up or down on megamergers? Depends on your point of view. More | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. News | Follow @EricPFierce

@CarlyHFierce: Yesterday's best-read on FP: Activists urge FDA to slap black-box warnings on lucrative testosterone boosters. Article | Follow @CarlyHFierce

> Pharma fights back against proposed changes to Medicare drug spending. Piece

> Boehringer Ingelheim withheld Pradaxa data from FDA, lawsuit files show. News

> Pharma shelled out $3.75B in fraud penalties in record-setting year, feds say. Story

Diagnostics News

> Daktari Diagnostics is raising up to $30M to support its Africa HIV test launch. Story

> Loyola team zeros in on an early-stage heart attack biomarker. Research

> Diagnostic Biochips is pursuing angel funding for a microchip brain implant. News

> A massive review reaffirms fecal test's place in colon cancer Dx. Article

> Tumor DNA can serve as noninvasive biomarker to stage and help treat cancer. Article

> Ezose Sciences will explore glycans as a possible Parkinson's biomarker. Brief

Drug Delivery News

> Clustered nanoparticles deliver chemo to fight drug-resistant ovarian cancer. News

> Inner-ear delivery device sends drugs out, draws fluid in. More

> FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. Story

> Teva snags an EU recommendation for its asthma, COPD inhaler. Article

> Single microparticle holds 3 different drugs for a cancer 1-2-3 punch. Piece

> Nanoparticles deliver chemotherapy when hit with a targeted light. Item

Pharma Marketing News

> Lilly's dulaglutide matches Victoza in study, but the real loser is AstraZeneca's Bydureon. Analysis

> Endo's off-label Lidoderm mantra, whistleblower says: 'Put the patch where the pain is.' Story

> GSK's new respiratory launches will give its revamped sales model a workout. News

> Even for busy doctors, 'nothing is as good as a rep' for getting pharma info. Article

> Amarin's future dims further as FDA nixes 5-year Vascepa exclusivity. Story

> Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story

> Thrombogenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps? Brief

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.